Merck's Emend Granted Broad Coverage Under Medicare Part B
This article was originally published in The Pink Sheet Daily
Executive Summary
The oral anti-emetic will be covered by Part B for first-line use in combination with dexamethasone and a 5-HT3 antagonist in patients receiving any of nine highly emetogenic chemotherapy agents under a final coverage decision memo. CMS loosens conditions for reimbursement in response to comments.